Complement C3 and C-reactive protein levels in patients with stable coronary artery disease

被引:60
作者
Ajjan, R [1 ]
Grant, PJ [1 ]
Futers, TS [1 ]
Brown, JM [1 ]
Cymbalista, CM [1 ]
Boothby, M [1 ]
Carter, AM [1 ]
机构
[1] Univ Leeds, Acad Unit Mol Vasc Med, LIGHT Labs, Leeds Inst Genet Hlth & Therapeut,Fac Med & Hlth, Leeds LS2 9JT, W Yorkshire, England
关键词
coronary artery disease; inflammation; C3; CRP; myocardial infarction;
D O I
10.1160/TH05-06-0384
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The aim of this study was to determine whether complement C3 is an indicator of coronary artery disease (CAD). We measured plasma C3 and CRP levels in 278 patients undergoing coronary angiography for typical symptoms of CAD and 269 healthy age and sex matched controls. C3 levels were significantly higher in patients compared with controls (1.15 g/l and 0.92 g/l respectively; p<0.001). In the patient group, C3 levels correlated with BMI, fasting glucose, HbAIc,fibrinogen, CRP and HDL in both men and women CRP levels were also higher in patients compared with controls (1.14 mg/l and 0.86 mg/l respect lively; p=0.005) and correlated with markers of the metabolic syndrome. In a logistic regression model including C3, smoking, hypertension, cholesterol and diabetes, C3 was independently associated with CAD with an odds ratio of 3.20 for a I SD increase in C3 levels. In contrast, CRP was not independently associated with CAD in a similar regression analysis. In conclusion, both C3 and CRP plasma levels are elevated in patients with symptoms of CAD. However, C3 seems to be a better indicator of CAD than CRP in this study, suggesting that C3 could be an additional marker for risk stratification in atherosclerosis.
引用
收藏
页码:1048 / 1053
页数:6
相关论文
共 26 条
[1]   HUMAN C'3 - EVIDENCE FOR LIVER AS PRIMARY SITE OF SYNTHESIS [J].
ALPER, CA ;
JOHNSON, AM ;
BIRTCH, AG ;
MOORE, FD .
SCIENCE, 1969, 163 (3864) :286-&
[2]   Beyond cholesterol: the enigma of atherosclerosis revisited [J].
Bhakdi, S ;
Lackner, KJ ;
Han, SR ;
Torzewski, M ;
Husmann, M .
THROMBOSIS AND HAEMOSTASIS, 2004, 91 (04) :639-645
[3]   Influence of C3 deficiency on atherosclerosis [J].
Buono, C ;
Come, CE ;
Witztum, JL ;
Maguire, GF ;
Connelly, PW ;
Carroll, M ;
Lichtman, AH .
CIRCULATION, 2002, 105 (25) :3025-3031
[4]   Preventative effects of rosiglitazone on restenosis after coronary stent implantation in patients with type 2 diabetes [J].
Choi, D ;
Kim, SK ;
Choi, SH ;
Ko, YG ;
Ahn, CW ;
Jang, YS ;
Lim, SK ;
Lee, HC ;
Cha, BS .
DIABETES CARE, 2004, 27 (11) :2654-2660
[5]  
CHOY LN, 1992, J BIOL CHEM, V267, P12736
[6]   Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease - Meta-analyses of prospective studies [J].
Danesh, J ;
Collins, R ;
Appleby, P ;
Peto, R .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 279 (18) :1477-1482
[7]   Troglitazone reduces hyperglycaemia and selectively acute-phase serum proteins in patients with Type II diabetes [J].
Ebeling, P ;
Teppo, AM ;
Koistinen, HA ;
Viikari, J ;
Rönnemaa, T ;
Nissén, M ;
Bergkulla, S ;
Salmela, P ;
Saltevo, J ;
Koivisto, VA .
DIABETOLOGIA, 1999, 42 (12) :1433-1438
[8]   Innate and adaptive immunity in the pathogenesis of atherosclerosis [J].
Hansson, GK ;
Libby, P ;
Schönbeck, U ;
Yan, ZQ .
CIRCULATION RESEARCH, 2002, 91 (04) :281-291
[9]   C-reactive protein is not associated with the presence or extent of calcified subclinical atherosclerosis [J].
Hunt, ME ;
O'Malley, PG ;
Vernalis, MN ;
Feuerstein, IM ;
Taylor, AJ .
AMERICAN HEART JOURNAL, 2001, 141 (02) :206-210
[10]  
Libby Peter, 2004, Am J Med, V116 Suppl 6A, p9S